
bioAffinity Technologies Investor Relations Material
Latest events

Status Update
bioAffinity Technologies

Q1 2025
15 May, 2025

Q4 2024
31 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from bioAffinity Technologies Inc
Access all reports
bioAffinity Technologies Inc. is a biotechnology company focused on addressing the critical need for non-invasive, early-stage cancer diagnosis and targeted cancer treatments. The company's flagship product, CyPath Lung, is a diagnostic test for the early detection of lung cancer. Additionally, the company is involved in research and development efforts aimed at creating targeted diagnostics and therapeutics to combat cancer, leveraging its core porphyrin platform technology. The company is headquartered in is headquartered in San Antonio, Texas, and its shares are listed on the Nasdaq.
Latest articles
)
Luca de Meo: Succeeding Pinault as the New CEO of Kering
Luca de Meo's leap from auto to luxury marks a bold new chapter as he becomes the first non-Pinault CEO to lead the Kering empire.
16 Jun 2025
)
Airbnb: The Hospitality Giant Without Property
Airbnb has grown from an idea to help the Co-Founders make rent, to one of the most dominant companies in the global hospitality industry.
13 Jun 2025
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
Ticker symbol
BIAF
Country
🇺🇸 United States